Angela Azar
Dermatology · Great Neck, NYNPI 1003988718
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 738 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 8.5% — the pattern of someone who eats at a lot of different presentations.
Across 738 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arcutis Biotherapeutics, Inc.$1K
- AbbVie$1K
- Pfizer$805
- Amgen$796
- Lilly USA, LLC$771
- Novartis$718
- plus $7K from 31 others
What the payments were for
- Food & beverage$12,21598%
- Education$2082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arcutis Biotherapeutics, Inc. | 60 | $1,054 |
| AbbVie(2 entities) | 56 | $1,004 |
| Pfizer | 53 | $805 |
| Amgen | 26 | $796 |
| Lilly USA, LLC | 54 | $771 |
| Novartis | 37 | $718 |
| Incyte Corporation | 45 | $655 |
| Dermavant Sciences, Inc. | 84 | $624 |
| Johnson & Johnson | 21 | $604 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 28 | $575 |
| LEO Pharma Inc. | 37 | $548 |
| Regeneron Healthcare Solutions, Inc. | 18 | $463 |
| Sanofi | 18 | $424 |
| Galderma Laboratories, L.p. | 27 | $389 |
| Smith+Nephew | 19 | $377 |
| VYNE Pharmaceuticals Inc. | 27 | $345 |
| Mayne Pharma Commercial LLC | 16 | $283 |
| Almirall LLC | 14 | $279 |
| Sun Pharmaceutical Industries Inc. | 11 | $225 |
| Organon | 10 | $212 |
| Merz North America, Inc. | 3 | $197 |
| Botanix SB Inc | 21 | $185 |
| E.r. Squibb & Sons, L.L.C. | 11 | $174 |
| Encore Dermatology Inc. | 15 | $140 |
| Biofrontera Inc. | 5 | $95 |
| EPI Health, LLC | 3 | $70 |
| Dermira, Inc. | 4 | $67 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Bristol Myers Squibb | 3 | $57 |
| Cipher Pharmaceuticals US LLC | 1 | $45 |
| Stemline Therapeutics Inc. | 2 | $38 |
| Journey Medical Corporation | 2 | $36 |
| Sebela Pharmaceuticals Inc. | 2 | $30 |
| UCB, Inc. | 1 | $25 |
| Shield Therapeutics Inc | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Glenmark Therapeutics Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,423 in reported general payments places this provider in the 80th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 34 | $126,881 |
| OpzeluraRuxolitinib Phosphate | 21 | $42,786 |
| CrotanCrotamiton | 11 | $27,848 |
| Pimecrolimus | 56 | $18,894 |
| Fluocinonide | 123 | $14,801 |
| VtamaTapinarof | 11 | $14,686 |
| Metronidazole | 113 | $14,630 |
| Ketoconazole | 366 | $11,233 |
| Clobetasol Propionate | 146 | $11,133 |
| FinaceaAzelaic Acid | 23 | $9,715 |
| Halobetasol Propionate | 131 | $8,504 |
| Azelaic Acid | 47 | $6,932 |
| Tacrolimus | 33 | $6,714 |
| Clindamycin Phosphate | 63 | $4,202 |
| Triamcinolone Acetonide | 164 | $2,302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $655 | $42,78621 claims |
| Dermavant Sciences, Inc.Vtama | $624 | $14,68611 claims |
| LEO Pharma Inc.Finacea | $548 | $9,71523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,151 dermatology providers in New York.
Other dermatology in Great Neck
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
- Emma GuttmanNew York$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.